Virpax Pharmaceuticals Inc Quick Ratio (VRPX) starting from the fourth quarter 2024 to fourth quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Virpax Pharmaceuticals Inc   (NASDAQ: VRPX)

Virpax Pharmaceuticals Inc 's Quick Ratio

VRPX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Virpax Pharmaceuticals Inc 's Cash & cash equivalent grew by 8682.04 % in the Q4 2024 sequentially, faster than Current Liabilities, this led to improvement in Virpax Pharmaceuticals Inc 's Quick Ratio to 0.61, Quick Ratio remained below Virpax Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 392 other companies have achieved higher Quick Ratio than Virpax Pharmaceuticals Inc in fourth quarter 2024. While Quick Ratio total ranking has improved so far during the Q4 2024 to 2250, from total ranking in the third quarter 2024 at 3523.

Explain Quick Ratio?
How much Cash & cash equivalents VRPX´s has?
What are VRPX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRPX Quick Ratio (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4
Y / Y Current Liabilities Change -70.73 % -63.94 % 227 % 235.63 % 122.79 %
Y / Y Cash & cash equivalent Change -83.45 % - - -89.01 % -51.87 %
Quick Ratio MRQ 0.61 0.01 0.35 0.43 1.08
VRPX's Total Ranking # 2250 # 3523 # 1881 # 1909 #
Seq. Current Liabilities Change 4.82 % -56.25 % 23.97 % -48.51 % 29.15 %
Seq. Cash & cash equivalent Change 8682.04 % -99.08 % 0.25 % -79.59 % -



Quick Ratio fourth quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 393
Healthcare Sector # 723
Overall Market # 2250


Quick Ratio Statistics
High Average Low
23.02 7.87 0.01
(Sep 30 2021)   (Sep 30 2024)




Financial Statements
Virpax Pharmaceuticals Inc 's Current Liabilities $ 2 Millions Visit VRPX's Balance sheet
Virpax Pharmaceuticals Inc 's Cash & cash equivalent $ 2 Millions Visit VRPX's Balance sheet
Source of VRPX's Sales Visit VRPX's Sales by Geography


Cumulative Virpax Pharmaceuticals Inc 's Quick Ratio

VRPX's Quick Ratio for the trailling 12 Months

VRPX Quick Ratio

 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth -18.74 % 54.75 % 125.85 % 78.04 % 41.42 %
Y / Y Cash & cash equivalent TTM Growth -79.84 % -64.16 % -77.22 % -86.67 % -72.9 %
Quick Ratio TTM 0.36 0.63 0.52 0.53 1.46
Total Ranking TTM # 3742 # 2878 # 1522 # 2637 #
Seq. Current Liabilities TTM Growth -29.08 % -16.91 % 17.84 % 17.03 % 35.07 %
Seq. Cash & cash equivalent TTM Growth -59.16 % 0.13 % 16.99 % -57.87 % -27.39 %

Quick ratio ranking by company, industry and sector >> Back to VRPX Financial Strength Comparisons >> Go to Compare VRPX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in VRPX's Current Liabilities to $2.47 millions, cumulative Quick Ratio to 0.36 below the VRPX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 459 other companies have achieved higher Quick Ratio than Virpax Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2024 from 2878 to 3742.

Explain Quick Ratio?
How much Cash & cash equivalents VRPX´s has?
What are VRPX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 460
Healthcare Sector # 951
Within the Market # 3742


trailing twelve months Quick Ratio Statistics
High Average Low
15.8 6.01 0.19
(Jun 30 2022)   (Jun 30 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2024 MRQ Cash & cash equivalentDec 31 2024 MRQ Current Liabilities
Amicus Therapeutics inc   1.68 $ 249.946  Millions$ 148.702  Millions
Alnylam Pharmaceuticals Inc   1.64 $ 2,686.348  Millions$ 1,638.782  Millions
Alkermes Plc   1.62 $ 751.668  Millions$ 465.199  Millions
Hookipa Pharma inc   1.61 $ 39.684  Millions$ 24.653  Millions
Immunic Inc   1.61 $ 35.668  Millions$ 22.175  Millions
Verrica Pharmaceuticals Inc   1.60 $ 46.329  Millions$ 29.012  Millions
Kamada Ltd   1.59 $ 78.435  Millions$ 49.389  Millions
Ensysce Biosciences Inc   1.59 $ 3.502  Millions$ 2.207  Millions
Alaunos Therapeutics Inc   1.58 $ 1.091  Millions$ 0.692  Millions
Pacira Biosciences inc   1.56 $ 484.615  Millions$ 309.920  Millions
Serina Therapeutics Inc   1.55 $ 3.672  Millions$ 2.366  Millions
Rockwell Medical inc   1.53 $ 21.602  Millions$ 14.091  Millions
Durect Corp  1.53 $ 11.803  Millions$ 7.710  Millions
Elicio Therapeutics Inc   1.53 $ 17.618  Millions$ 11.523  Millions
Cormedix Inc   1.53 $ 51.688  Millions$ 33.840  Millions
Enveric Biosciences Inc   1.50 $ 2.241  Millions$ 1.490  Millions
Grace Therapeutics Inc  1.50 $ 3.280  Millions$ 2.185  Millions
Canton Strategic Holdings Inc   1.47 $ 3.559  Millions$ 2.414  Millions
Quantum Cyber N v   1.47 $ 6.363  Millions$ 4.319  Millions
Sellas Life Sciences Group Inc   1.47 $ 13.986  Millions$ 9.510  Millions
Corvus Pharmaceuticals Inc   1.47 $ 51.964  Millions$ 35.402  Millions
Inflarx N V  1.42 $ 20.817  Millions$ 14.664  Millions
Rani Therapeutics Holdings Inc   1.39 $ 27.639  Millions$ 19.891  Millions
Evolus Inc   1.38 $ 86.952  Millions$ 62.960  Millions
Axsome Therapeutics Inc   1.37 $ 315.353  Millions$ 230.104  Millions
Iterum Therapeutics Plc  1.37 $ 24.125  Millions$ 17.605  Millions
Imunon Inc   1.36 $ 5.873  Millions$ 4.334  Millions
Bioxcel Therapeutics Inc   1.34 $ 29.854  Millions$ 22.233  Millions
Evoke Pharma Inc   1.31 $ 13.597  Millions$ 10.380  Millions
Nucana Plc  1.31 $ 14.203  Millions$ 10.851  Millions

Date modified: 2026-06-22T14:32:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.